CJC-1295 with DAC Research: What 5 Studies Show (2026) | RetatrutideCompare

CJC-1295 with DAC — 5 studies indexed on PubMed. Albumin-conjugated GHRH analog providing days-long elevation of GH and IGF-1 — distinct from the pulsatile pattern of native GHRH. Half-life: ~6–8 days (albumin-bound). FDA status: Not FDA-approved.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on CJC-1295 with DAC?

There are approximately 5 studies indexed on PubMed that mention CJC-1295 with DAC (CJC-1295 DAC, Drug Affinity Complex GHRH), based on a search last updated 2026-06-18.

Is CJC-1295 with DAC FDA-approved?

FDA status: Not FDA-approved.

How does CJC-1295 with DAC work?

Albumin-conjugated GHRH analog providing days-long elevation of GH and IGF-1 — distinct from the pulsatile pattern of native GHRH.

Reference facts

Also known as: CJC-1295 DAC, Drug Affinity Complex GHRH
Category: Growth Hormone & Ghrelin
Mechanism of action: Albumin-conjugated GHRH analog providing days-long elevation of GH and IGF-1 — distinct from the pulsatile pattern of native GHRH.
Targets: GHRHR
Indications under research or approved: Off-label research
Regulatory status (reference entry): Not FDA-approved
Half-life: ~6–8 days (albumin-bound)
Sequence: YADAIFTNSYRKVLGQLSARKLLQDIMSR
Sequence notes: CJC-1295 backbone with maleimidopropionyl-Lys30 that covalently conjugates to circulating albumin in vivo, extending half-life to ~6 days.
Molecular weight (Da): 3647
First reported: 2005

Primary References

Teichman et al., JCEM 2006

Explore research articles about CJC-1295 with DAC

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.